Introduction
The study of cancer care in the older population is a complex task. The word "complex" derives from the Latin cum plexere, meaning to weave together. In an older person, many interwoven conditions may conspire to reduce life expectancy, the tolerance of stress, and the ability to live independently. 1 Anemia in an older person is an example of such a complexity, because it may be affected by multiple causes, including hemopoietic insufficiency, chronic renal dysfunction, chronic inflammation, and iron deficiency from chronic bleeding and iron malabsorption. 2 The study of cancer care in the older population must take into account the complexity of aging; therefore, as described in this article, a multipronged approach is needed for this patient population.
Definition of Age
Aging is associated with common trends that include a decreased functional reserve of multiple organ systems and an increased susceptibility to diseases and injuries. 1 These changes occur at different rates in different individuals and are poorly reflected in chronological age. The assessment of physiological, rather than chronological, age is paramount to the enrollment of older individuals in clinical trials of cancer treatment. Chronological age may be used as a landmark to establish when the assessment of physiological age becomes necessary, and this landmark is commonly established to be 70 years of age 3 ; how-ever, this statement does not imply that all individuals 70 years of age and older are elderly.
Assessment of Physiological Age
Age is associated with decreased life expectancy and tolerance of stress. Thus, the determination of physiological age may be based on the assessment of mortality risk and stress-related complications. For this purpose, the best validated instrument is a Comprehensive Geriatric Assessment (CGA; Table 1 ). [3] [4] [5] Activities of daily living (ADLs) are activities necessary to basic survival and include transferring, eating, grooming, dressing, going to the bathroom alone, and continence. A person dependent in at least 1 ADL requires a full-time caregiver or admission to an assisted-living facility. In general, patients dependent in at least 1 ADL have a limited life expectancy, a limited tolerance for stress, and are candidates for palliative care; however, exceptions do exist. If a patient who was previously independent is now ADL dependent due to a treatable neoplastic condition, such as lymphoma, then treatment is indicated. In these situations, treatment may reverse ADL dependence. Instrumental activities of daily living (IADLs) are activities necessary to live independently and include the use of transportation, ability to take medications, to use the telephone, to manage one's finances, and to provide to one's meals. A person dependent in one or more IADLs will require assistance. The determination of IADLs is relevant to this review, because it implies an increased incidence of therapeutic complications in addition to an increased mortality risk. 6, 7 Presently, polymorbidity is a more popular term than comorbidity, implying that different diseases may influence both the treatment and the behavior of other diseases. 8 Polymorbidity is associated with a decreased life expectancy, decreased tolerance to antineoplastic treatment and, in general, a poor cancer prognosis. 3 Geriatric syndromes include common conditions, although not all are unique to aging. 9 Patients with cancer, ADL dependence, and at least 1 geriatric syndrome are candidates for symptom control, unless the geriatric syndrome is reversible. Malnutrition is a common complication of both cancer and aging and is associated with a decreased tolerance of chemotherapy and decreased immune function. 10 In addition to the CGA, other forms of assessing physiological age are noteworthy. The frailty index is calculated by summing the functional deficits in an aging person. 11 Physiological age is assessed based on the average number of deficits accumulated by a person of that chronological age. For example, if a 75-year-old woman has the number of deficits that correspond to an average 61-year-old, the woman's physiological age is assessed as 61 years. However, determining the frailty index is too laborious for clinical applications because it requires the clinician to evaluate 70 conditions 11 ; in addition, it is not clear whether the index predicts mortality risks and tolerance of stress.
Numerous laboratory tests have been proposed for the assessment of physiological aging. Of these, the assessment of inflammatory markers in the circulation 12 and the length of leukocyte telomeres 13 bear a relation to mortality risk. Telomere length also predicts the risk of adverse events from cytotoxic chemotherapy. 14 Although these tests are of interest, they have not been validated. The determination of inflammatory markers lacks ad- 
Influence of Aging on Cancer Treatment
Factors related to aging that may influence cancer treatment include cancer biology, which may be different among younger and older patients; decreased life expectancy of the older person, which may reduce the benefits of cancer treatment; and increased vulnerability to complications due to cancer therapies.
Biology of Cancer and Aging
Cancer growth and aggressiveness are influenced by 2 factors, namely, the tumor cell and the tumor host. For example, acute myeloid leukemia is less susceptible to treatment in the elderly patient population, and this is due -at least in part -to the higher prevalence of unfavorable prognostic factors, including complex cytogenetic changes, MDR-1 gene expression, and the involvement of the early multipotential hemopoietic progenitors. 15 By contrast, in the setting of breast cancer, the prevalence of favorable prognostic factors, such as hormone receptor concentration and good cellular differentiation, increases with age. 16 Genomic and proteomic analysis may help account for these factors in clinical trials.
Assessment of patient-related factors is difficult. Such factors may include immunosenescence, endocrine senescence, proliferative senescence, and chronic inflammation. 17 Animal data suggest that immunosenescence may have different effects on the growth of various neoplasms; for example, immunosenescence may enhance the growth of highly immunogenic neoplasms, while disfavoring the growth of poorly immunogenic neoplasms. Decreased production of sexual hormones may inhibit hormone-dependent cancers, such as breast and prostate cancers.
Age is associated with increased insulin resistance, which results in an increased concentration of insulin, a powerful growth factor for several tumors, in the circulation. 18 The aging of stromal tissues involves the proliferative senescence of fibroblasts, facilitating neoplastic growth with the production of tumor growth factors and enzymes that dissolve basal membranes. 19 Age is also associated with progressive and chronic inflammation, which may contribute to immunosenescence and tumor growth. 17 Polypharmacy is another patient-related factor among the older population because the number of medications used and the prevalence of polypharmacy increase with age. 8 For example, the use of metformin, a drug that decreases insulin resistance and, consequently, circulating levels of insulin, is associated with prolonged survival in patients with prostate or breast cancer. 20, 21 As mentioned previously, polymorbidity may also affect cancer growth. For example, the prognosis of breast, prostate, or large bowel cancer is worse in individuals with diabetes than in those without diabetes. 8 At present, these factors cannot be accounted for in randomized clinical trials.
Treatment Goals
The risk-benefit ratio of antineoplastic treatment may be reduced in the majority of older individuals. The expected benefits are lower in this population due to a progressive decline in life expectancy. Even in the most fit of older persons, individual age is a risk factor for some complications of chemotherapy, including myelosuppression, mucositis, cardiomyopathy, and peripheral neuropathy. 22 The risk of such complications increases in individuals with compromised function and multiple morbidities.
It is reasonable to aim for a cure when facing a rapidly lethal but curable disease, such as large B-cell lymphoma or acute leukemia, despite the high risk of serious complications. Currently, it is reasonable not to submit older individuals with limited life expectancies and a chronic, but not life-threatening disease, such as chronic lymphocytic leukemia, to the toxicity of fludarabine, cyclophosphamide, and rituximab, 23 which may add a few months of survival at a time when most patients might have died of a disease other than cancer.
Cure, prolongation of survival, and symptom management are the main goals of treatment; however, the preservation of function and active life expectancy should also be goals for older patients. 24 Active life expectancy is a period of time during which a person remains functionally independent. Loss of functional independency is a significant threat to the quality of life of older individuals. 24 
Barriers to Treatment
Numerous social factors may preclude cancer treatment in older patients, including accessibility (eg, many older individuals may not be able to negotiate their way alone to a treatment center), difficulty with finances (recipients of Medicare may have to pay unaffordable co-payments for cancer treatment), and inadequate home support. However, it is important to remember that ageism can be a hindrance to the reception of adequate cancer treatment. 25 A study conducted by the Cancer and Leukemia Group B (CALGB) demonstrated that the main obstacle to clinical trial participation of older patients with breast cancer was the reluctance of physicians to offer experimental treatment to older individuals. 25 Clinical studies of cancer treatment among older patients must account for the factors outlined in this brief review, including a poor understanding of the interaction between tumor and patient, a reduced risk-benefit ratio, the increased risk of treatment complications, the inclusion of active life expectancy among the treatment goals, and the socioeconomic barriers to treatment.
Clinical Trials in Older Patients With Cancer
Aging may be associated with a number of pharmacological changes that render the study of new drugs in the older population necessary (Table 2) . 22 Data on drug absorption are wanted, but the bioavailability of oral drugs is expected to decrease with age. Decreased total body water content is associated with a decreased volume of distribution and an increased level of water-soluble drugs in the circulation, which may purportedly increase toxicity. Renal excretion and hepatic metabolism of drugs are universally decreased with age. Although the decline in the glomerular filtration rate may be accounted for by calculating the level of creatinine clearance, a clinical test of hepatic metabolism is still needed. As already mentioned, numerous age-related changes in target organs may be associated with increased hemopoietic, mucosal, cardiac, and neurological toxicities. The question of whether a new agent is effective and safe in both the younger and older patient populations must be addressed in appropriate clinical trials.
Advanced age should never be a criterion to exclude older individuals from participating in clinical trials designed for adults. Rather, as clinicians, we must ask whether certain clinical trials should be exclusively dedicated to older individuals.
Phase 1 and 2 Trials
Older individuals should have access to phase 1 trials, but reserving clinical trials for older individuals alone is not a productive strategy. Due to the increased risk of adverse effects in the older population, phase 1 trials dedicated to older individuals may unnecessarily delay the development and approval of life-saving drugs. Instead, a representation of individuals 70 years or older in phase 2 trials should be adequate to establish the activity and the safety of a new drug among this older population. In my opinion, phase 2 trials represent a convenient way to study the pharmacology of new agents among the elderly without delaying drug development.
Phase 3 Trials
Phase 3 trials dedicated to the elderly may be conducted for 2 reasons: (1) to determine whether the benefits of a treatment strategy decline with age, and (2) whether the use of new drugs may improve the treatment of elderly patients who are not candidates for more aggressive treatment.
In a seminal study of the CAL-GB, women 65 years of age or older with early-stage breast cancer were randomized to receive combination chemotherapy or single-agent capecitabine. 26 The study showed that combination chemotherapy in the adjuvant setting reduced recurrence rates and improved survival among these patients. This study resolved a decade-long controversy of whether adjuvant chemotherapy was beneficial to older women. Other important studies of this type demonstrated that doublet chemotherapy was superior to single-agent chemotherapy in older patients with metastatic non-small-cell lung cancer 27 and that full-dose chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone was superior to chemotherapy in reduced doses among elderly patients with large cell lymphoma.
28 These tri- Central nervous system Atrophy Increase in degenerative processes with decreased circulation als determined that age alone is not a contraindication to active cancer treatment; however, these trials included healthy elderly patients, and, thus, shed no light on the best treatment options for elderly persons affected by disability and multiple morbidities. A 2014 study demonstrated that elderly patients with diseases and disability can be studied in randomized controlled trials. 29 Individuals with chronic lymphocytic leukemia who were 70 years of age or older and not eligible for more aggressive treatment (eg, combination fludarabine, cyclophosphamide, and rituximab) were randomized to receive chlorambucil or chlorambucil plus rituximab or obinutuzumab. Nearly 1,500 patients were stratified during randomization according to comorbidity severity. Disease-free and overall survival rates were improved in patients treated with obinutuzumab. The results from this recent study represent a model for future randomized controlled studies among older patients with an estimated life expectancy of several years.
Future Directions
The Figure illustrates how future studies might be conducted. To estimate a patient's life expectancy, the use of ePrognosis (http://eprognosis.ucsf.edu; University of California, San Francisco) is recommended, which is available free of charge. 4 To estimate an older person's risk of grade 3/4 toxicity, I recommend the Chemotherapy Risk Assessment Scale for High-Age Patients and the Cancer and Aging Research Group instruments, both of which have been validated in older individuals. 6, 7 Of course, the risk of toxicity that disqualifies an individual from a trial may vary from disease to disease. For example, the threshold may be higher in cases in which the disease is rapidly lethal and the treatment option offers an opportunity for cure or prolonged survival.
Other Studies in Older Patients With Cancer
Clinical trials exclusively dedicated to older patients will still be unable to embrace the diversity of this patient population. The questions that persist include:
• Is the treatment beneficial to the majority of older individuals?
• Which individual factors determine the benefit and risk of treatment in the older population?
Studies that match Surveillance Epidemiology and End Results data with Medicare records may provide a partial answer to the first question above. Because of these data, it was possible to discern that individuals 75 years and older benefit from the adjuvant treatment of colon and rectal cancers 30 and that adjuvant chemotherapy is leukemogenic in older women. 31 However, it is impossible to establish from these results exactly which patients may benefit and which ones may be harmed by cytotoxic chemotherapy, as it is not possible to analyze certain prognostic factors from these data.
A prospective evaluation of these patients alone is the way to build prognostic models that encompass the variabilities among the older patient population, including all of the factors with the potential to interact with treatment options. Through this process, models were derived to estimate the risk of chemotherapy complications in older individuals. 6, 7 The advent of the electronic medical record offers a unique opportunity to perform studies in such a way that the majority of older patients with cancer can be included in research trials. As long as all relevant information related to function, comorbidity, emotional status, and social support is included within the medical record, it may become possible to create precise prognostic models that help deliver personalized care to older patients with cancer. Such is the aim of the project CancerLinQ, which is a system designed by the American Society of Clinical Oncology. 
Conclusions
Age should not be considered a criterion for disqualifying a person with cancer from a clinical trial. Phase 2 trials dedicated to older individuals are necessary to establish the pharmacology of novel agents in the older patient population. Phase 3 trials that study the older patient population should stratify patients according to life expectancy and treatment risks. Registry studies with prospective data collection are necessary to encompass the diversity of all older individuals.
